Physician profile
Earl E Lloyd
NPI 1669524658
$22,874.65
in general payments reported to CMS, 2019-2025
72 companies · $3,236 in 2025
The $3,236 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $2,410 · 2021: $4,077 · 2022: $3,823 · 2023: $3,508 · 2024: $3,710 · 2025: $3,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,421.23 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,149.37 | 2019-2025 | |
| Novo Nordisk INC | $2,522.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,856.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,436.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,304.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,167.51 | 2019-2025 | Otezla, Repatha, Repatha |
| Arbor Pharmaceuticals, INC. | $947.21 | 2019-2022 | |
| Pfizer INC. | $896.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $842.18 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $603.73 | 2019-2022 | |
| Astellas Pharma US INC | $603.37 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $538.49 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $464.38 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.20 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $444.59 | 2019-2024 | Xarelto |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $411.97 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $350.72 | 2021-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $345.46 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $340.64 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Abbott Laboratories | $314.23 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $312.15 | 2024-2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $305.61 | 2021-2025 | Trintellix |
| Esperion Therapeutics, INC. | $278.26 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.47 | 2021-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $224.16 | 2022-2023 | Quviviq |
| Daiichi Sankyo INC. | $202.00 | 2019-2024 | Injectafer |
| Lundbeck LLC | $189.40 | 2023-2025 | Rexulti, Vyepti |
| Kowa Pharmaceuticals America, INC. | $148.84 | 2021-2022 | |
| Medtronic, INC. | $133.17 | 2021-2025 | Intellis Adaptivestim |
| Exact Sciences Corporation | $130.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $128.42 | 2021 | |
| Azurity Pharmaceuticals, INC. | $125.86 | 2023-2024 | Edarbi, Edarbi |
| Ironwood Pharmaceuticals, INC | $110.61 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $105.33 | 2020-2022 | |
| Eisai INC. | $67.73 | 2021-2025 | |
| Seqirus USA INC | $67.29 | 2019-2022 | |
| Mylan Specialty L.P. | $58.50 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $57.11 | 2019-2024 | Ajovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $56.84 | 2022 | |
| Philips North America LLC | $55.96 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $50.64 | 2019-2020 | |
| Edwards Lifesciences Corporation | $50.23 | 2025 | Sapien 3 Ultra Resilia |
| Kerecis Limited | $48.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Shield Therapeutics INC | $43.05 | 2024 | |
| Stryker Corporation | $42.12 | 2022 | |
| Dexcom, INC. | $41.94 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $38.45 | 2021 | |
| Phathom Pharmaceuticals, INC. | $37.73 | 2023-2025 | Voquezna |
| Radius Health, INC. | $36.48 | 2019-2020 | |
| Grifols USA, LLC | $34.58 | 2024 | Prolastin-C Liquid |
| Ionis Pharmaceuticals, INC. | $30.90 | 2025 | Tryngolza |
| Vanda Pharmaceuticals INC. | $29.59 | 2025 | Fanapt, Hetlioz |
| Currax Pharmaceuticals LLC | $29.57 | 2021-2025 | Contrave |
| Verona Pharma, INC. | $29.45 | 2025 | Ohtuvayre |
| Axonics, INC. | $27.86 | 2024 | Axonics, Bulkamid |
| Ultragenyx Pharmaceutical INC. | $27.04 | 2021-2022 | |
| Boston Scientific Corporation | $24.29 | 2025 | Watchman Flx |
| Ethicon US, LLC | $24.03 | 2020 | |
| Sk Life Science, INC. | $23.05 | 2023 | |
| Sumitomo Pharma America, INC. | $18.71 | 2024 | Gemtesa |
| Amneal Pharmaceuticals LLC | $18.42 | 2023 | Unithroid |
| Ibsa Pharma INC. | $15.49 | 2022 | |
| Nabriva Therapeutics, Plc | $15.21 | 2021 | |
| Electromed, INC. | $14.70 | 2021 | |
| Acadia Pharmaceuticals INC | $14.53 | 2025 | Nuplazid |
| Genentech USA, INC. | $13.85 | 2021 | |
| Inspire Medical Systems, INC. | $13.58 | 2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $13.46 | 2021 | |
| Sanofi Pasteur INC. | $12.65 | 2019 | |
| Medtronic Minimed, INC. | $12.62 | 2020 | |
| Horizon Therapeutics Plc | $10.81 | 2019 | |
| Cardiovascular Systems INC. | $7.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.